Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem
Autore:
Drover, D; Lemmens, H; Naidu, S; Cevallos, W; Darwish, M; Stanski, D;
Indirizzi:
Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA Stanford Univ Stanford CA USA 94305 pt Anesthesia, Stanford, CA 94305 USA Wyeth Ayerst Res, Radnor, PA USA Wyeth Ayerst Res Radnor PA USAWyeth Ayerst Res, Radnor, PA USA
Titolo Testata:
CLINICAL THERAPEUTICS
fascicolo: 12, volume: 22, anno: 2000,
pagine: 1443 - 1461
SICI:
0149-2918(200012)22:12<1443:PPARP>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO; VOLUNTEERS; CL-284,846; SINGLE; MODEL;
Keywords:
population pharmacokinetics; pharmacodynamics; zaleplon; zolpidem;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Drover, D Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA Stanford Univ Stanford CA USA 94305 sia, Stanford, CA 94305 USA
Citazione:
D. Drover et al., "Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem", CLIN THER, 22(12), 2000, pp. 1443-1461

Abstract

Objective: This study compared the pharmacokinetics, pharmacodynamics, andpharmacokinetic/pharmacodynamic (PK/PD) profile of zaleplon, a new pyrazolopyrimidine hypnotic, with those of zolpidem and placebo. Methods: This was a double-blind, 5-period crossover study in which healthy volunteers with no history of sleeping disorder were randomized to 10- or20-mg oral doses of zalepion, 10- or 20-mg oral doses of zolpidem, or placebo. The pharmacokinetic characteristics of the active drugs were estimatedusing a noncompartmental method and NONMEM. Pharmacodynamic characteristics were determined using psychophysical tests, including measures of sedation, mood, mental and motor speed, and recent and remote recall. Results of these tests were used to compare the drugs' relative PK/PD profiles. Results: Ten healthy male and female volunteers, aged 23 to 31 years,took part in the study. The apparent elimination half-life of zaleplon (60.1 +/- 8.9 min) was significantly shorter than that of zolpidem (124.5 +/- 37.9 min) (P < 0.001). Zaleplon produced less sedation than zolpidem at the2 doses studied (P < 0.001). The sedation scores of the zalepion groups returned to baseline in less time than those of the zolpidem groups (4 vs 8 hours; P < 0.05). Zaleplon had no effect on recent or remote recall, whereaszolpidem had a significant effect on both measures (P < 0.05). Conclusions: In this study in 10 young, healthy volunteers, zaleplon was eliminated more rapidly, produced no memory loss, and caused less sedation than zolpidem at the same doses.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 13:16:14